Novel Tricyclic Compounds as TLR7 Agonists for Treating Cancer.

Provided herein are novel tricyclic compounds as ERK5 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Provided herein are novel tricyclic compounds, pharmaceutical compositions, use of such compounds in treating bacterial infections, and processes for preparing such compounds.

Provided herein are novel bicyclic compounds as TLR7 agonists, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

4954498 Tricyclic benzimidazole compounds, pharmaceutical compositions and methods of use: Alfred Mertens, Saal Wolfgang von der, Erwi Boehm, Klaus Strein, Schriesheim, Federal Republic Of Germany assigned to Boehringer Mannheim GmbH

Provided herein are novel tricyclic triazolo compounds as DGK inhibitors, pharmaceutical compositions, use of such compounds in treating metastatic melanoma and processes for preparing such compounds.

5116843 Tricyclic benzimidazole compounds, pharmaceutical compositions and methods of use: Alfre Mertens, Saal Wolfgang von der, Erwi Boehm, Klaus Strein, Schriesheim, Federal Republic of Germany assigned to Boehringer Mannheim GmbH

Toll-like receptors (TLRs) have been shown to play an important role in the immune system, which warrants study of their remarkable potential as pharmacological targets. Activation of TLRs requires participation from specific pathogen-associated molecular patterns (PAMPs) and accessory proteins such as myeloid differentiation protein 2 (MD2), lipopolysaccharide binding protein (LBP), and cluster differentiation antigen 14 (CD14). Assembly of the TLR4-MD2-LPS complex is essential in TLR4 activation. Recent studies have revealed that TLR4 activation is a significant trigger of signal transmission pathways in the nervous system, which could result in chronic pain as well as opioid tolerance and dependence. Researchers of the molecular structure of TLRs and their accessory proteins have opened a door to syntheses of TLRs agonists and antagonists, such as eritoran. Small-molecule modulators of TLR4, such as MD2-I and tricyclic antidepressants, offer more promising prospects than peptides, given their convenience in oral administration and lower cost. Herein we mainly discuss the mechanisms and clinical prospects of TLR4 agonists and antagonists.

4801753 Biologically active tricyclic compounds and pharmaceutical compositions containing same: David S Savage, Thoma Sleigh, John Clark, Glasgow, United Kingdom assigned to Akzona Incorporated

Provided herein are novel imidazo[4,5-c]pyridine compounds as TLR7 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.